Palisade Bio PALI
NASDAQ PALI
$1.44 +0.01 (+0.70%)
At close: Oct 2, 2026 · 4:00 PM EDT

Palisade Bio (PALI) Gains from Sales and Divestitures (2024)

Updated

Palisade Bio (PALI) posted Gains from Sales and Divestitures of -$4,000 for FY2024.

Analysis

Palisade Bio (PALI) Gains from Sales and Divestitures (2024) Analysis & Trends

Since FY2016, Palisade Bio has reported Gains from Sales and Divestitures for 4 years.

  • The FY2024 figure stands as the lowest annual Gains from Sales and Divestitures since FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Palisade Bio 249.98 Mn -146.46 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 -4,000.00
API Access

Palisade Bio Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=PALI&period=max&api_key=YOUR_API_KEY